We are deeply concerned in case of a full acquisition of Monsanto as Bayer would not have the debt capacity, and issuing shares with a more than 60 percent lower valuation before any premium is value destroying, this is reflected by the weak share price reaction in the market. A formation of a JV or a no premium merger (at prices before deal announcements) would be a much better solution for Bayer.